Holger Eidtmann

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

Gϋnter von Minckwitz, Michael Untch, Jens‐Uwe Blohmer et al. · Journal of Clinical Oncology · 2012 · 2.6K citations

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

José Baselga, Ian Bradbury, Holger Eidtmann et al. · The Lancet · 2012 · 1.3K citations · Full text

Breast Oncology, Oncology, Pathology +5

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

Michael Gnant, Brigitte Mlineritsch, Walter Schippinger et al. · New England Journal of Medicine · 2009 · 1K citations · Full text

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

Gϋnter von Minckwitz, Andreas Schneeweiß, Sibylle Loibl et al. · The Lancet Oncology · 2014 · 1K citations

Gbg 66, Breast Oncology, Medicine +7

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab

Roberto Salgado, Carsten Denkert, Christine Campbell et al. · JAMA Oncology · 2015 · 589 citations · Full text